Last reviewed · How we verify
ABP 710
ABP 710 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.
ABP 710 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | ABP 710 |
|---|---|
| Sponsor | Amgen |
| Drug class | TNF-α inhibitor (monoclonal antibody biosimilar) |
| Target | TNF-α (tumor necrosis factor-alpha) |
| Modality | Biologic |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
ABP 710 is designed as a biosimilar to Humira (adalimumab), a fully human monoclonal antibody that binds and neutralizes TNF-α, a key inflammatory cytokine. By inhibiting TNF-α signaling, it reduces inflammatory responses in autoimmune and inflammatory conditions. As a biosimilar, ABP 710 is manufactured through recombinant DNA technology and is intended to have comparable efficacy and safety to the reference product.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Polyarticular juvenile idiopathic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Serious infections
- Tuberculosis reactivation
Key clinical trials
- Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
- MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease (NA)
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABP 710 CI brief — competitive landscape report
- ABP 710 updates RSS · CI watch RSS
- Amgen portfolio CI